CPC C07D 235/30 (2013.01) [A61P 35/00 (2018.01); C07D 405/06 (2013.01)] | 20 Claims |
1. A method of treating a subject having a disease by inhibiting an HDAC isoform, comprising administering to the subject a compound of formula (I):
wherein:
X is selected from the group consisting of: H, halo, —C1-C6 alkyl, aryl, —C3-C7 cycloalkyl, and -3- to 10-membered heterocycle, any of which is unsubstituted, or substituted with one or more of: -halo, —C1-C6 alkyl, —O—(C1-C6 alkyl), —OH, —CN, —COOR′, —OC(O)R′, NHR′, N(R′)2, —NHC(O)R′, and —C(O)NHR′, wherein R′ is —H or —C1-C6 alkyl;
A is selected from the group consisting of: a bond, —C1-C6 alkyl, and —C3-C7 cycloalkyl, any of which is unsubstituted, or substituted with one or more of: -halo, —C1-C6 alkyl, —O—(C1-C6 alkyl), —OH, —CN, —COOR′, —OC(O)R′, NHR′, N(R′)2, —NHC(O)R′, and —C(O)NHR′, wherein R′ is —H or —C1-C6 alkyl;
Y is selected from the group consisting of: H, —C1-C6 alkyl, —C3-C7 cycloalkyl, aryl, and -3- to 10-membered heterocycle, any of which is unsubstituted, or substituted with one or more of: -halo, —C1-C6 alkyl, —O—(C1-C6 alkyl), —OH, —CN, —COOR′, —OC(O)R′, NHR′, N(R′)2, —NHC(O)R′, and —C(O)NHR′, wherein R′ is —H or —C1-C6 alkyl; and
Q is selected from the group consisting of: —H, -halo, —C1-C6 alkyl, —O—(C1-C6 alkyl), —OH, —CN, —COOR′, —OC(O)R′, NHR′, N(R′)2, —NHC(O)R′, and —C(O)NHR′, wherein R′ is —H or —C1-C6 alkyl;
wherein the compound inhibits the histone deacetylating activity of the HDAC isoform and the disease is a cancer selected from the group consisting of colon cancer, diffuse large B-cell lymphoma (DLBCL), hepatocellular carcinoma, Hodgkin's lymphoma, leukemia, lung cancer, neuroblastoma, non-Hodgkin's lymphoma, pancreatic ductal adenocarcinoma, peripheral T-cell lymphoma, prostate cancer, and Waldenstrom myeloma.
|